Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: October 17, 2022 Report Code: GDME1449EPD-ST

Select Item

Drugs of abuse tests are used for the detection of illegal and/or prescribed substances in the patent samples including urine, blood, saliva, or sweat. The drugs of abuse pipeline market research report provide comprehensive information about the drugs of abuse pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Moreover, the report provides information about various pipeline products and their estimated approval dates.

Drugs of Abuse Pipeline Products Market Segmentation by Territories

The key territories with products in the pipeline are the US and Europe, among others. The US is the leading territory in the drugs of abuse pipeline products market.

Drugs of Abuse Pipeline Products Market Analysis by Territories, 2022 (%)

Drugs of Abuse Pipeline Products Market Analysis by Territories

For more territory insights into the drugs of abuse pipeline products market, download a free report sample

Drugs of Abuse Pipeline Products Market Segmentation by Regulatory Paths

The drugs of abuse pipeline report provide detailed insights into the pipeline products by a regulatory path including 510(k), CE, and CE-IVD. Most of the products follow the 510(k) pathway to enter the market. 

Drugs of Abuse Pipeline Products Market Analysis by Regulatory Paths, 2022 (%)

Drugs of Abuse Pipeline Products Market Analysis by Regulatory Paths

For more regulatory path insights into the drugs of abuse pipeline products market, download a free report sample

Drugs of Abuse Pipeline Products Market - Competitive Landscape

Some of the leading companies in the drugs of abuse pipeline products market are Accelerate Diagnostics Inc, Adaltis Srl, Banyan Biomarkers Inc, Behavioral Diagnostics Inc, BioMark Technologies Inc, Ceres Nanosciences Inc, genedrive plc, Horiba Ltd, OpalGenix Inc, Randox Laboratories Ltd, Roche Diagnostics International Ltd, and SDI Biomed Inc.

Accelerate Diagnostics Inc: Accelerate Diagnostics Inc (Accelerate) is an in vitro diagnostics company engaged in the development and commercialization of instruments for the identification and testing of antibiotic susceptibility to infectious pathogens. The company operates a manufacturing facility in Tucson, Arizona. It sells products directly and through a network of third-party distributors to hospital microbiology laboratories in domestic and foreign countries.

Adaltis Srl: Adaltis Srl (Adaltis), a subsidiary of BATM Advanced Communications Ltd, is an international IVD company that develops, manufactures, and markets in-vitro diagnostic systems and reagents. The company’s products include IVD instruments, IVD reagents, molecular diagnostic instruments, molecular diagnostic tests, accessories, consumables, and spare parts.

Banyan Biomarkers Inc: Banyan Biomarkers Inc (Banyan Biomarkers) is a medical technology company that commercializes vitro diagnostic tests for the detection of traumatic brain injury and neurological diseases. The company’s product pipeline includes biomarkers for depression, hypoxic ischemic encephalopathy, neuro ICU monitoring, sub-acute or chronic traumatic brain injury, and stroke.

Drugs of Abuse Pipeline Products Market Report Overview

Key Territories The US and Europe
Analysis Year 2022
Key Regulatory Paths 510(k), CE, and CE-IVD
Leading Companies Accelerate Diagnostics Inc, Adaltis Srl, Banyan Biomarkers Inc, Behavioral Diagnostics Inc, BioMark Technologies Inc, Ceres Nanosciences Inc, genedrive plc, Horiba Ltd, OpalGenix Inc, Randox Laboratories Ltd, Roche Diagnostics International Ltd, and SDI Biomed Inc

Drugs of Abuse Pipeline Products Market Territories Outlook (2022)

  • The US
  • Europe

Drugs of Abuse Pipeline Products Market Regulatory Paths Outlook (2022)

  • 510(k)
  • CE
  • CE-IVD

Scope

  • Extensive coverage of the drugs of abuse under development

  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details, and other developmental activities

  • The report reviews the major players involved in the development of drugs of abuse and lists all their pipeline projects

  • The coverage of pipeline products is based on various stages of development ranging from early development to the approved/issued stage

  • The report provides key clinical trial data of ongoing trials specific to pipeline products

  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage

  • Identify and understand important and diverse types of drugs of abuse under development

  • Develop market-entry and market expansion strategies

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

Accelerate Diagnostics Inc
Adaltis Srl
Banyan Biomarkers Inc
Behavioral Diagnostics Inc
BioMark Technologies Inc
Ceres Nanosciences Inc
genedrive plc
Horiba Ltd
OpalGenix Inc
Randox Laboratories Ltd
Roche Diagnostics International Ltd
SDI Biomed, Inc.
SensoDXII LLC
Siemens Healthcare Diagnostics Inc
Siemens Healthineers AG
Thermo Fisher Scientific Inc
University of California San Francisco
ZORA Biosciences Oy

Table of Contents

  • Table of Contents

    • 1.1 List of Tables

    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Drugs of Abuse Overview

  • 3 Products under Development

    • 3.1 Drugs of Abuse – Pipeline Products by Stage of Development

    • 3.2 Drugs of Abuse – Pipeline Products by Territory

    • 3.3 Drugs of Abuse – Pipeline Products by Regulatory Path

    • 3.4 Drugs of Abuse – Pipeline Products by Estimated Approval Date

  • 4 Drugs of Abuse – Pipeline Products under Development by Companies

    • 4.1 Drugs of Abuse Companies – Pipeline Products by Stage of Development

    • 4.2 Drugs of Abuse – Pipeline Products by Stage of Development

  • 5 Drugs of Abuse Companies and Product Overview

    • 5.1 Accelerate Diagnostics Inc Company Overview

      • 5.1.1 Accelerate Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 Adaltis Srl Company Overview

      • 5.2.1 Adaltis Srl Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Banyan Biomarkers Inc Company Overview

      • 5.3.1 Banyan Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 Behavioral Diagnostics Inc Company Overview

      • 5.4.1 Behavioral Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 BioMark Technologies Inc Company Overview

      • 5.5.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 Ceres Nanosciences Inc Company Overview

      • 5.6.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 genedrive plc Company Overview

      • 5.7.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 Horiba Ltd Company Overview

      • 5.8.1 Horiba Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 OpalGenix Inc Company Overview

      • 5.9.1 OpalGenix Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 Randox Laboratories Ltd Company Overview

      • 5.10.1 Randox Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.11 Roche Diagnostics International Ltd Company Overview

      • 5.11.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.12 SDI Biomed, Inc. Company Overview

      • 5.12.1 SDI Biomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.13 SensoDXII LLC Company Overview

      • 5.13.1 SensoDXII LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.14 Siemens Healthcare Diagnostics Inc Company Overview

      • 5.14.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.15 Siemens Healthineers AG Company Overview

      • 5.15.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview

    • 5.16 Thermo Fisher Scientific Inc Company Overview

      • 5.16.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.17 University of California San Francisco Company Overview

      • 5.17.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview

    • 5.18 ZORA Biosciences Oy Company Overview

      • 5.18.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Drugs of Abuse- Recent Developments

    • 6.1 Sep 14, 2022: Horiba announces Review of First Half of 2022

    • 6.2 Sep 06, 2022: Labcorp to Speak at the Baird 2022 Global Healthcare Conference

    • 6.3 Aug 24, 2022: New line of electrochemistry bench meters simplify pH, conductivity and dissolved oxygen measurement

    • 6.4 Aug 12, 2022: Horiba announce Summary of Consolidated Financial Statements for the Six Months Ended June 30, 2022

    • 6.5 Aug 09, 2022: OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year

    • 6.6 Jul 28, 2022: Labcorp Announces 2022 Second Quarter Results

    • 6.7 May 17, 2022: Labcorp to Speak at the UBS 2022 Global Healthcare Conference

    • 6.8 May 10, 2022: OraSure Reports 1Q22 Record Revenue of $67.7 Million +16% Year-Over-Year With 21% Growth in Non-COVID Revenue

    • 6.9 May 04, 2022: Labcorp to Webcast Its Annual Meeting of Shareholders

    • 6.10 Apr 11, 2022: Thermo Fisher Scientific to Host Investor Day

    • 6.11 Mar 22, 2022: OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role

    • 6.12 Feb 23, 2022: Orasure Technologies Reports 4q21 Revenue of $63.6 Million; Inteliswab® Production Scales Up

    • 6.13 Feb 14, 2022: Horiba announces Summary of Consolidated Financial Statements for the Year Ended December 31, 2021

    • 6.14 Feb 02, 2022: Salimetrics expands laboratory CLIA Certification for Saliva Testing

    • 6.15 Jan 04, 2022: Labcorp to Speak Virtually at the 40th Annual J.P. Morgan Healthcare Conference

    • 6.16 Dec 31, 2021: Improve Medical Instruments Announces on the Resignation of the Secretary of the Board of Directors and the Appointment of the Secretary of the Board of Directors

    • 6.17 Nov 12, 2021: Psychemedics Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021

    • 6.18 Nov 11, 2021: Horiba Announces Summary of Consolidated Financial Statements for the Nine Months Ended September 30, 2021

    • 6.19 Nov 03, 2021: OraSure Technologies Reports 3Q21 Revenue of $53.9 Million

    • 6.20 Nov 02, 2021: Labcorp to Speak at Credit Suisse 30th Annual Healthcare Conference

  • 7 Appendix

    • 7.1 Methodology

    • 7.2 About GlobalData

    • 7.3 Contact Us

    • 7.4 Disclaimer

Table

Drugs of Abuse – Pipeline Products by Stage of Development 9

Drugs of Abuse – Pipeline Products by Territory 10

Drugs of Abuse – Pipeline Products by Regulatory Path 11

Drugs of Abuse – Pipeline Products by Estimated Approval Date 12

Drugs of Abuse Companies – Pipeline Products by Stage of Development 13

Drugs of Abuse – Pipeline Products by Stage of Development 14

Accelerate Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Accelerate Pheno System – Intra-Abdominal Infections Assay – Product Status 15

Accelerate Pheno System – Intra-Abdominal Infections Assay – Product Description 16

Accelerate Pheno System – Urinary Tract Infections Assay – Product Status 16

Accelerate Pheno System – Urinary Tract Infections Assay – Product Description 16

Adaltis Srl Pipeline Products & Ongoing Clinical Trials Overview 17

CLIAgen Steroid Assay – Product Status 17

CLIAgen Steroid Assay – Product Description 17

Banyan Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 18

Diagnostic Assay – Alcoholism – Product Status 18

Diagnostic Assay – Alcoholism – Product Description 18

Behavioral Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 19

Epigenetic Test – Alcohol Abstinence – Product Status 19

Epigenetic Test – Alcohol Abstinence – Product Description 19

BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 20

ABA-SUBSTANCE – Product Status 20

ABA-SUBSTANCE – Product Description 20

Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Nanotrap Fentanyl Assay – Product Status 21

Nanotrap Fentanyl Assay – Product Description 21

genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 22

Genedrive – OPRM1 Assay – Product Status 22

Genedrive – OPRM1 Assay – Product Description 22

Horiba Ltd Pipeline Products & Ongoing Clinical Trials Overview 23

Pentra C200 Analyzer – DAU Assay – Product Status 23

Pentra C200 Analyzer – DAU Assay – Product Description 23

OpalGenix Inc Pipeline Products & Ongoing Clinical Trials Overview 24

GPS-Opioid – Product Status 24

GPS-Opioid – Product Description 24

Randox Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 25

Rx Daytona – Oxycodone Assay – Product Status 25

Rx Daytona – Oxycodone Assay – Product Description 25

Rx Daytona – Propoxyphene Assay – Product Status 26

Rx Daytona – Propoxyphene Assay – Product Description 26

RX Imola Cotinine Test – Product Status 26

RX Imola Cotinine Test – Product Description 26

RX Imola Oxycodone Test – Product Status 27

RX Imola Oxycodone Test – Product Description 27

RX Imola Propoxyphene Test – Product Status 27

RX Imola Propoxyphene Test – Product Description 27

Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

Chromate (SV) Assay – Product Status 28

Chromate (SV) Assay – Product Description 28

Oxidant (SV) Assay – Product Status 29

Oxidant (SV) Assay – Product Description 29

pH Assay – Product Status 29

pH Assay – Product Description 29

Specific Gravity Assay – Product Status 30

Specific Gravity Assay – Product Description 30

THC Oral Fluid Assay – Product Status 30

THC Oral Fluid Assay – Product Description 30

SDI Biomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

SDI CA 480 – Drugs Of Abuse Assay – Product Status 31

SDI CA 480 – Drugs Of Abuse Assay – Product Description 31

SensoDXII LLC Pipeline Products & Ongoing Clinical Trials Overview 32

SensoDx Drug Screen – Product Status 32

SensoDx Drug Screen – Product Description 32

Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Dimension RxL Max Test – Meperidine – Product Status 33

Dimension RxL Max Test – Meperidine – Product Description 33

Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 34

Dimension RxL Max Test – Oxycodone – Product Status 34

Dimension RxL Max Test – Oxycodone – Product Description 34

Dimension RxL Max Test – Tramadol – Product Status 35

Dimension RxL Max Test – Tramadol – Product Description 35

Viva-E Drug Testing System – Syva Emit DAT 6 Acetyl Morphine Assay – Product Status 35

Viva-E Drug Testing System – Syva Emit DAT 6 Acetyl Morphine Assay – Product Description 35

Viva-Jr Drug Testing System – Syva Emit DAT 6 Acetyl Morphine Assay – Product Status 36

Viva-Jr Drug Testing System – Syva Emit DAT 6 Acetyl Morphine Assay – Product Description 36

Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 37

Cascadion SM Clinical Analyzer – Drugs Of Abuse Assay – Product Status 37

Cascadion SM Clinical Analyzer – Drugs Of Abuse Assay – Product Description 37

University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 38

Steroid Detection Assay – Product Status 38

Steroid Detection Assay – Product Description 38

ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 39

Statin Intolerance Risk Test – Product Status 39

Statin Intolerance Risk Test – Product Description 39

Glossary 63

Figures

Drugs of Abuse – Pipeline Products by Stage of Development 9

Drugs of Abuse – Pipeline Products by Territory 10

Drugs of Abuse – Pipeline Products by Regulatory Path 11

Drugs of Abuse – Pipeline Products by Estimated Approval Date 12

Frequently asked questions

Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update in real time.

  • Access a live Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more